Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNKS | O95271 | 4/20 | 0.42 |
| ▸ | TNKS2 | Q9H2K2 | 4/20 | 0.42 |
| ▸ | PARP1 | P09874 | 3/20 | 0.42 |
| ▸ | PDE9A | O76083 | 1/20 | 0.37 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.37 |
| ▸ | RAF1 | P04049 | 3/20 | 0.36 |
| ▸ | BRAF | P15056 | 3/20 | 0.36 |
| ▸ | IGF1R | P08069 | 6/20 | 0.36 |
| ▸ | SYK | P43405 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.35 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.34 |
| ▸ | PIK3R2 | O00459 | 1/20 | 0.34 |
| ▸ | AURKA | O14965 | 1/20 | 0.33 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.33 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31230030 | 1.00 | TNKS (0.42) | TNKSTNKS2PARP1PDE9APARP2 | |
| SCHEMBL21633377 | 0.81 | TNKS (0.41) | TNKSTNKS2PARP1IGF1RCYP3A4 | |
| SCHEMBL31230090 | 0.81 | TNKS (0.41) | TNKSTNKS2PARP1IGF1RCYP3A4 | |
| SCHEMBL21633056 | 0.80 | PARP1 (0.40) | TNKSTNKS2PARP1IGF1RCYP3A4 | |
| SCHEMBL21633197 | 0.79 | CNR2 (0.41) | TNKSTNKS2PARP1PDE9APARP2 | |
| SCHEMBL31230123 | 0.79 | TNKS (0.41) | TNKSTNKS2PARP1IGF1RCYP3A4 | |
| SCHEMBL21633099 | 0.79 | TNKS (0.41) | TNKSTNKS2PARP1IGF1RCYP3A4 | |
| Hydrochloric Acid SCHEMBL21633204 | 0.79 | CNR2 (0.41) | TNKSTNKS2PARP1PDE9APARP2 | |
| SCHEMBL21632885 | 0.78 | KDM4A (0.41) | TNKSTNKS2PARP1PDE9APARP2 | |
| Hydrochloric Acid SCHEMBL31230418 | 0.77 | KDM4A (0.41) | TNKSTNKS2PARP1PDE9APARP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220089609-A1 | SUBSTITUTED QUINAZOLINONE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR4 | DOMAIN THERAPEUTICS (FR) | 2022-03-24 | — | — | US | claimed |
| EP-3827001-A1 | SUBSTITUTED QUINAZOLINONE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR4 | Domain Therapeutics (FR) | 2021-06-02 | — | — | EP | claimed |
| WO-2020021064-A1 | SUBSTITUTED QUINAZOLINONE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR4 | DOMAIN THERAPEUTICS (FR) | 2020-01-30 | — | — | WO | claimed |
| US-20220089609-A1 | SUBSTITUTED QUINAZOLINONE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR4 | DOMAIN THERAPEUTICS (FR) | 2022-03-24 | — | — | US | disclosed |
| EP-3827001-A1 | SUBSTITUTED QUINAZOLINONE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR4 | Domain Therapeutics (FR) | 2021-06-02 | — | — | EP | disclosed |
| WO-2020021064-A1 | SUBSTITUTED QUINAZOLINONE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR4 | DOMAIN THERAPEUTICS (FR) | 2020-01-30 | — | — | WO | disclosed |
| WO-2020021064-A1 | SUBSTITUTED QUINAZOLINONE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR4 | DOMAIN THERAPEUTICS (FR) | 2020-01-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220089609-A1 | SUBSTITUTED QUINAZOLINONE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR4 | GRIK4, GRM4, GRIA4 | TNKS 3832/4885TNKS2 3994/4885PARP1 4711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.